An investigation for investors in bluebird bio Inc (NASDAQ:BLUE) shares over potential securities laws violations by bluebird bio Inc was announced and NASDAQ:BLUE stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com

San Diego, CA -- (SBWire) -- 06/23/2015 --An investigation on behalf of investors of bluebird bio Inc (NASDAQ:BLUE) shares over potential securities laws violations by bluebird bio and certain of its directors and officers in connection certain financial statements was announced.

Investors who purchased shares of bluebird bio Inc (NASDAQ:BLUE), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of bluebird bio Inc (NASDAQ:BLUE) concerning whether a series of statements by bluebird bio Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On June 9, 2015, bluebird bio Inc announced the completion of the National Institutes of Health (NIH) Recombinant DNA Advisory Committee's (RAC) public review of the HGB-208 pediatric study protocol for bluebird bio's LentiGlobin BB305 product candidate in beta-thalassemia major. The RAC recommendation was to delay initiation of the study in the United States for one to two years. Shares of bluebird bio Inc (NASDAQ:BLUE) declined on June 10, 2015, to $178.02 per share, respectively as low as $169.62 per share on June 19, 2015.

Those who purchased shares of bluebird bio Inc (NASDAQ:BLUE) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com